Responses
Clinical/translational cancer immunotherapy
Original research
Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
Compose a Response to This Article
Other responses
No responses have been published for this article.
